Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus
暂无分享,去创建一个
L. Magder | M. Petri | A. Ranger | Yuji Zhang | N. Allaire | W. Fu | P. Cullen
[1] Adam R. Johnson,et al. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. , 2017, JCI insight.
[2] V. Pascual,et al. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis , 2016, Rheumatology.
[3] A. Midgley,et al. Increased expression of low density granulocytes in juvenile-onset systemic lupus erythematosus patients correlates with disease activity , 2016, Lupus.
[4] P. Merkel,et al. Neutrophil‐Related Gene Expression and Low‐Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2015, Arthritis & rheumatology.
[5] J. Bienkowska,et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year , 2015, Lupus Science & Medicine.
[6] Virginia Pascual,et al. Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures , 2014, Arthritis & rheumatology.
[7] S. Greenberg,et al. The Plasma Cell Signature in Autoimmune Disease , 2014, Arthritis & rheumatology.
[8] D. Isenberg,et al. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. , 2013, Arthritis and rheumatism.
[9] K. Elkon,et al. Type I IFN system in the development and manifestations of SLE , 2012, Current opinion in rheumatology.
[10] Gerald McGwin,et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.
[11] Mariana J. Kaplan,et al. Neutrophils in the pathogenesis and manifestations of SLE , 2011, Nature Reviews Rheumatology.
[12] Matthias Kretzler,et al. Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus , 2011, The Journal of Immunology.
[13] V. Pascual,et al. The interferon-α signature of systemic lupus erythematosus , 2010, Lupus.
[14] Virginia Pascual,et al. An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.
[15] Abdul Hakkim,et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis , 2010, Proceedings of the National Academy of Sciences.
[16] W. Mccune,et al. A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs , 2010, The Journal of Immunology.
[17] M. Petri,et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus , 2009, Lupus.
[18] P. Schneider,et al. Cracking the BAFF code , 2009, Nature Reviews Immunology.
[19] D. Gladman,et al. Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus , 2008, Annals of the rheumatic diseases.
[20] H. Nossent,et al. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time , 2006, Lupus.
[21] Mimi Y. Kim,et al. Combined oral contraceptives in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.
[22] D. Hilbert,et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels , 2005, Arthritis research & therapy.
[23] P. Gregersen,et al. The emerging role of interferon in human systemic lupus erythematosus. , 2004, Current opinion in immunology.
[24] M. Peterson,et al. Coordinate overexpression of interferon‐α–induced genes in systemic lupus erythematosus , 2004 .
[25] V. Roschke,et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. , 2003, Arthritis and rheumatism.
[26] Virginia Pascual,et al. Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.
[27] G. Karypis,et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] V. Roschke,et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. , 2001, Arthritis and rheumatism.
[29] J. Kalbfleisch,et al. Between- and within-cluster covariate effects in the analysis of clustered data. , 1998, Biometrics.
[30] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[31] D. Sackett,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.
[32] J F Fries,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.
[33] M. Peterson,et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. , 2004, Arthritis and rheumatism.
[34] M. Petri,et al. Validity and reliability of lupus activity measures in the routine clinic setting. , 1992, The Journal of rheumatology.